Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 9/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | GLB1 | P16278 | 2/20 | 0.61 |
| ▸ | PYGL | P06737 | 2/20 | 0.61 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.61 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | AGL | P35573 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7403169 | 0.83 | — | — | |
| SCHEMBL18478110 | 0.83 | GBA1 (0.76) | GBA1GAAGLB1PYGLGBA2 | |
| Afegostat SCHEMBL2714841 | 0.76 | GBA1 (1.00) | GBA1GAAGLB1PYGLGBA2 | |
| Afegostat SCHEMBL21575618 | 0.76 | GBA1 (1.00) | GBA1GAAGLB1PYGLGBA2 | |
| Afegostat SCHEMBL2357291 | 0.76 | GBA1 (1.00) | GBA1GAAGLB1PYGLGBA2 | |
| Afegostat SCHEMBL24514726 | 0.76 | GBA1 (1.00) | GBA1GAAGLB1PYGLGBA2 | |
| Afegostat SCHEMBL12232220 | 0.76 | GBA1 (1.00) | GBA1GAAGLB1PYGLGBA2 | |
| Afegostat SCHEMBL2435705 | 0.76 | GBA1 (1.00) | GBA1GAAGLB1PYGLGBA2 | |
| Afegostat SCHEMBL3062308 | 0.76 | GBA1 (1.00) | GBA1GAAGLB1PYGLGBA2 | |
| Afegostat SCHEMBL2435882 | 0.76 | GBA1 (1.00) | GBA1GAAGLB1PYGLGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | claimed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | claimed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | claimed |
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| US-6894046-B2 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-17 | — | — | US | disclosed |
| US-20050054618-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | RYTVED KLAUS ASGER (DK) | 2005-03-10 | — | — | US | disclosed |
| EP-1133482-B1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-23 | — | — | EP | disclosed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
| EP-0749423-B1 | PIPERIDINES AND PYRROLIDINES | NOVO NORDISK AS (DK) | 2003-06-18 | — | — | EP | disclosed |
| US-20020010177-A1 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN CILAG S.A. (FR) | 2002-01-24 | — | — | US | disclosed |
| US-5863903-A | ANTIDIABETIC AGENT | NOVO NORDISK A/S (DK) | 1999-01-26 | — | — | US | disclosed |
| EP-0749423-A1 | PIPERIDINES AND PYRROLIDINES | NOVO NORDISK A/S (DK) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024391-A1 | PIPERIDINES AND PYRROLIDINES | NOVO NORDISK A/S (DK) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054618-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GBA1 308/4885GAA 43/4885GLB1 198/4885 |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GBA1 308/4885GAA 43/4885GLB1 198/4885 |
| US-20020010177-A1 | IL-5 inhibiting 6-azauracil derivatives | ALOX5, IL5, IL6ST | GBA1 4303/4885GAA 4722/4885GLB1 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.